Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Working Capital Changes (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Other Working Capital Changes for 10 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 96.45% year-over-year to $3.5 million, compared with a TTM value of $2.9 million through Dec 2025, up 32.09%, and an annual FY2025 reading of $2.9 million, up 32.09% over the prior year.
  • Other Working Capital Changes was $3.5 million for Q4 2025 at Zevra Therapeutics, up from -$2.5 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $3.5 million in Q4 2025 and bottomed at -$2.5 million in Q3 2025.
  • Average Other Working Capital Changes over 5 years is $230950.0, with a median of -$31000.0 recorded in 2022.
  • The sharpest move saw Other Working Capital Changes crashed 548.81% in 2021, then skyrocketed 3958.33% in 2023.
  • Year by year, Other Working Capital Changes stood at -$1.7 million in 2021, then skyrocketed by 95.63% to -$74000.0 in 2022, then skyrocketed by 335.14% to $174000.0 in 2023, then skyrocketed by 920.69% to $1.8 million in 2024, then skyrocketed by 96.45% to $3.5 million in 2025.
  • Business Quant data shows Other Working Capital Changes for ZVRA at $3.5 million in Q4 2025, -$2.5 million in Q3 2025, and $2.2 million in Q2 2025.